News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Erasca, Inc.
Erasca Reports First Quarter 2024 Business Updates and Financial Results
May 08, 2024
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca Announces $45 Million Oversubscribed Private Placement Financing
March 27, 2024
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
March 27, 2024
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
February 14, 2024
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
NVS
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
December 11, 2023
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
November 28, 2023
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca Reports Third Quarter 2023 Financial Results and Business Updates
November 09, 2023
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca to Present at Upcoming Investor Conferences in November
November 08, 2023
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca to Present at the Cantor Global Healthcare Conference
September 19, 2023
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca Reports Second Quarter 2023 Financial Results and Business Updates
August 10, 2023
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca Reports First Quarter 2023 Financial Results and Business Updates
May 15, 2023
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates
March 23, 2023
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors
December 20, 2022
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors
December 13, 2022
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
December 09, 2022
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
NVS
Erasca Announces Pricing of Underwritten Offering of Common Stock
December 09, 2022
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination
November 30, 2022
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca to Present at Upcoming Investor Conferences
November 22, 2022
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca Reports Third Quarter 2022 Financial Results and Business Updates
November 09, 2022
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination
October 20, 2022
From
Erasca, Inc.
Via
GlobeNewswire
Tickers
ERAS
PFE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close